OCUGEN, INC. Operating Lease Right-of-Use Assets
OCUGEN, INC. (OCGN) had Operating Lease Right-of-Use Assets of $4.09 million as of 2025-12-31, per its 10-K filed 2026-03-04.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:OperatingLeaseRightOfUseAsset · last filed 2026-03-04
- 2025-12-31: Operating Lease, Right-of-Use Asset $4.09M.
- 2024-12-31: Operating Lease, Right-of-Use Asset $3.61M.
- 2023-12-31: Operating Lease, Right-of-Use Asset $3.94M.
- 2022-12-31: Operating Lease, Right-of-Use Asset $3.91M.
| Period end | Operating Lease, Right-of-Use Asset | Operating Lease, Right-of-Use Asset as first filed |
|---|---|---|
| 2025-12-31 | $4.09M 10-K · filed 2026-03-04 | |
| 2024-12-31 | $3.61M 10-K · filed 2026-03-04 | |
| 2023-12-31 | $3.94M 10-K · filed 2025-03-05 | |
| 2022-12-31 | $3.91M 10-K · filed 2024-04-16 | |
| 2022-09-30 | $4.04M 10-Q · filed 2022-11-08 | |
| 2022-06-30 | $4.17M 10-Q · filed 2022-08-05 | |
| 2022-03-31 | $1.42M 10-Q · filed 2022-05-06 | |
| 2021-12-31 | $1.59M 10-K · filed 2023-02-28 | |
| 2021-09-30 | $1.43M 10-Q · filed 2021-11-09 | |
| 2021-06-30 | $1.48M 10-Q · filed 2021-08-06 | |
| 2021-03-31 | $1.53M 10-Q · filed 2021-05-07 | |
| 2020-12-31 | $434.00K 10-K · filed 2022-02-28 | $433.65K 10-K · filed 2021-03-19 |
| 2020-09-30 | $217.51K 10-Q · filed 2020-11-06 | |
| 2020-06-30 | $260.71K 10-Q · filed 2020-08-14 | |
| 2020-03-31 | $302.99K 10-Q · filed 2020-05-08 | |
| 2019-12-31 | $344.57K 10-K · filed 2021-03-19 | |
| 2019-09-30 | $385.09K 10-Q · filed 2019-11-12 | |
| 2019-06-30 | $424.87K 8-K/A · filed 2019-10-07 | |
| 2019-03-31 | $6.43M 10-Q · filed 2019-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B |